Department of Psychiaty, Beitou Branch, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan.
Faculty of Nursing Department, Meiho University, Pingtung City, Taiwan; Department of Addiction Science, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung City, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Lancet Healthy Longev. 2021 Aug;2(8):e479-e488. doi: 10.1016/S2666-7568(21)00140-9. Epub 2021 Jul 21.
People with dementia die prematurely. Identifying differences in mortality rates between different types of dementia might aid in the development of preventive interventions for the most vulnerable populations. The aim of this study was to compare the difference in mortality rates between individuals without dementia and individuals with various types of dementia.
For this systematic review and meta-analysis, we did a systematic search of MEDLINE, PubMed, Embase, and Cochrane Library from inception to July 11, 2020, for cross-sectional or cohort studies that assessed mortality and survival-related outcomes among people with different types of dementia compared with people without dementia. Single-arm studies without comparison groups and autopsy studies or family studies that used a selected sample were excluded. The Newcastle-Ottawa Scale was used by two authors (D-JL and C-SC) independently to measure the methodological quality of included studies, and two authors (F-CY and P-TT) independently extracted data. We assessed differences in all-cause mortality rate and survival time from dementia diagnosis between individuals without dementia, individuals with Alzheimer's disease, and individuals with non-Alzheimer's disease dementias. The secondary outcomes were age at death and survival time from disease onset. Random-effects meta-analyses were done. Effect sizes included hazard ratios (HRs) and mean differences (MDs) with 95% CIs. Potential moderators, including age-associated moderators, were identified through meta-regression and subgroup analyses. This study is registered with PROSPERO, CRD42020198786.
Our database search identified 11 973 records, and we included 78 eligible studies in our analyses, encompassing 63 125 individuals with dementia and 152 353 controls. Individuals with any type of dementia had a higher mortality rate than individuals without dementia (HR 5·90, 95% CI 3·53 to 9·86), and the HR for all-cause mortality was highest for Lewy body dementia (17·88, 5·87 to 54·46). After diagnosis, the mean survival time for people with Alzheimer's disease was 5·8 years (SD 2·0). Compared with people with Alzheimer's disease, a diagnosis of any non-Alzheimer's disease dementia was associated with a higher risk of all-cause mortality (HR 1·33, 1·21 to 1·46), a shorter survival time from diagnosis (MD -1·12 years, 95% CI -1·52 to -0·72), and a younger age at death (-1·76 years, -2·66 to -0·85). Survival time from disease onset was also shorter in people with non-Alzheimer's dementia, across types, compared with people with Alzheimer's disease, but the subgroup analysis revealed that this difference was only significant for vascular dementia (MD -1·27 years, -1·90 to -0·65) and dementia with Lewy bodies (MD -1·06 years, -1·68 to -0·44). The interactions between age and several survival-related outcomes were significant. 39 (50%) of the 78 included studies were rated as good quality, and large heterogeneity (I>75%) was observed for most of the study outcomes.
Alzheimer's disease is the most common type of dementia and one of the major causes of mortality worldwide. However, the findings from the current study suggest that non-Alzheimer's disease dementias were associated with higher morality rates and shorter life expectancy than Alzheimer's disease. Developing tailored treatment and rehabilitation programmes for different types of dementia is important for mental health providers, patients, and their families.
None.
痴呆症患者的寿命往往较短。确定不同类型痴呆症之间的死亡率差异可能有助于为最脆弱人群制定预防干预措施。本研究旨在比较无痴呆症个体和各种类型痴呆症个体之间的死亡率差异。
本系统评价和荟萃分析纳入了从建库至 2020 年 7 月 11 日在 MEDLINE、PubMed、Embase 和 Cochrane Library 上进行的评估不同类型痴呆症患者与无痴呆症患者死亡率和生存相关结局的横断面或队列研究。排除无对照组的单臂研究和使用选择性样本的尸检研究或家族研究。两位作者(D-JL 和 C-SC)独立使用纽卡斯尔-渥太华量表评估纳入研究的方法学质量,两位作者(F-CY 和 P-TT)独立提取数据。我们评估了无痴呆症个体、阿尔茨海默病个体和非阿尔茨海默病痴呆个体之间的全因死亡率和从痴呆症诊断开始的生存时间差异。次要结局为死亡年龄和从疾病发病开始的生存时间。采用随机效应荟萃分析。效应量包括风险比(HR)和 95%置信区间(CI)的均值差异(MD)。通过荟萃回归和亚组分析确定潜在的调节因素,包括与年龄相关的调节因素。本研究已在 PROSPERO 注册,CRD42020198786。
我们的数据库检索确定了 11973 条记录,纳入了 78 项符合条件的研究,共纳入 63125 名痴呆症患者和 152353 名对照者。任何类型的痴呆症患者的死亡率均高于无痴呆症患者(HR 5.90,95%CI 3.53-9.86),路易体痴呆症的全因死亡率最高(HR 17.88,5.87-54.46)。诊断后,阿尔茨海默病患者的平均生存时间为 5.8 年(SD 2.0)。与阿尔茨海默病患者相比,任何非阿尔茨海默病痴呆症的诊断与全因死亡率增加相关(HR 1.33,1.21-1.46),从诊断开始的生存时间缩短(MD-1.12 年,95%CI-1.52 年至-0.72 年),死亡年龄降低(MD-1.76 岁,-2.66 岁至-0.85 岁)。与阿尔茨海默病患者相比,非阿尔茨海默病痴呆患者的疾病发病后生存时间也较短,但亚组分析显示,这种差异仅在血管性痴呆(MD-1.27 年,-1.90 年至-0.65 年)和路易体痴呆(MD-1.06 年,-1.68 年至-0.44 年)中显著。年龄与几种生存相关结局之间的交互作用具有统计学意义。78 项纳入研究中,39 项(50%)被评为高质量,大多数研究结果的异质性较大(I>75%)。
阿尔茨海默病是最常见的痴呆症类型,也是全球主要的死亡原因之一。然而,本研究结果表明,非阿尔茨海默病痴呆症与更高的死亡率和更短的预期寿命相关,而非阿尔茨海默病痴呆症。为不同类型的痴呆症制定针对性的治疗和康复方案对精神卫生服务提供者、患者及其家属都很重要。
无。